Resultados de Búsqueda

Evidencias COVID-19

CEBM

We are currently aware of 11 trials of remdesivir in COVID-19. The number of patients to be studied in the masked trials is 2,061 out of 22,437 in total (9.2%). The results of the remdesivir use program suggest, but do not prove, that the benefits of remdesivir may outweigh the harm it might cause. However, the death rate from COVID-19 is relatively low, so an open, uncontrolled trial will never be able to define benefits or harms. Does Remdesivir Save COVID-19 Patients? A definitive answer ...

Evidencias COVID-19

CEBM

With other cytokines, interferons are responsible for some of the symptoms of viral infection, including fever and muscle pain. Microbial products and chemical inducers can also stimulate interferon production. Interferons also have effects on tumour cell survival via TLRs. Most available formulations are for subcutaneous injection. The licensed subcutaneous formulations are contraindicated in patients with current severe depression or suicidal ideation or both. Interferons have not, up to ...

Prescrire bilan. Towards better patient care: drugs to avoid

Prescrire International

The medicinal clays attapulgite, diosmectite, hydrotalcite, and montmorillonite beidellitique aka monmectite and kaolin are used alone or in multi-ingredient products to treat various intestinal disorders including diarrhea, heartburn, and gastroesophageal reflux disease. They should be avoided due to the lead they contain. Lead has neurological effects, hematological, renal, cardiovascular and reproductive toxicity, and the severity of most of these toxic effects increases with the dose to ...

Evidencias COVID-19

IHCAI – DIME. Información seleccionada sobre intervenciones para el tratamiento de COVID-19

Comparison of remdesivir with ribavirin, favipiravir, oseltamivir, and umfenovir as treatment for COVID-19 infection. In addition to antiretrovirals, evidence suggests that these should be accompanied by oxygen therapy, fluid maintenance, electrolyte balance, and intestinal microbiological modulators with nutritional support

Prescrire bilan. Towards better patient care: drugs to avoid

Prescrire International

When used systemically, expose patients to an increased risk of gastrointestinal and skin disorders (including Stevens-Johnson syndrome and toxic epidermal necrolysis) but they are no more effective than other NSAIDs.